Cargando…

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma

Histologic transformation has been described as an acquired mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We herein report the case of a woman with stage IV lung adenocarcinoma harboring EGFR exon 19 deletions who was initially treated with EGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hakozaki, Taiki, Kitazono, Miyako, Takamori, Mikio, Kiriu, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303443/ https://www.ncbi.nlm.nih.gov/pubmed/32101830 http://dx.doi.org/10.2169/internalmedicine.3542-19

Ejemplares similares

Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review
por: Hakozaki, Taiki, et al.
Publicado: (2019)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
por: Sato, Mitsuo, et al.
Publicado: (2018)

Acute Fibrinous and Organizing Pneumonia with Myelodysplastic Syndrome: Corticosteroid Monotherapy Led to Successful Ventilator Weaning
por: Yamamoto, Mari, et al.
Publicado: (2016)

Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
por: Hong, Er, et al.
Publicado: (2022)

Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR‐mutated lung adenocarcinoma: a report of two cases
por: Uruga, Hironori, et al.
Publicado: (2020)

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
por: Koba, Hayato, et al.
Publicado: (2021)

EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
por: Takuma, Sho, et al.
Publicado: (2021)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Erratum to NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
Publicado: (2022)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
por: Xu, Hui, et al.
Publicado: (2020)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015)

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report
por: Hakozaki, Taiki, et al.
Publicado: (2018)

PD-L1 expression in small cell lung cancer: should we designate it for assignment?
por: Hakozaki, Taiki
Publicado: (2021)

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report
por: Moriya, Rika, et al.
Publicado: (2017)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small‐cell lung cancer
por: Hao, Lidan, et al.
Publicado: (2023)

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report
por: Ma, Shuxiang, et al.
Publicado: (2020)

Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde
por: Wysota, Michael, et al.
Publicado: (2020)

Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer
por: Bai, Wenwen, et al.
Publicado: (2021)

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
por: Digiacomo, Nunzio, et al.
Publicado: (2023)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies
por: IZUMI, HIROKI, et al.
Publicado: (2015)

Risk factors for post-bronchoscopy pneumonia: a case–control study
por: Sato, Yu, et al.
Publicado: (2020)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib
por: Teixeira, Carlos Henrique A., et al.
Publicado: (2020)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

Heterogeneity or transformation? A whack‐a‐mole case of EGFR‐mutant lung adenocarcinoma and small cell carcinoma: A case report
por: Ninomaru, Taira, et al.
Publicado: (2022)

Epidermal growth factor receptor mutated oligometastatic adeno-squamous lung cancer transformation to small cell lung cancer
por: O’Leary, Connor G, et al.
Publicado: (2018)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
por: Miyazaki, Shinichi, et al.
Publicado: (2020)

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
por: Liao, Jiatao, et al.
Publicado: (2021)

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
por: Kusaba, Yusaku, et al.
Publicado: (2022)

Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
por: Frankel, Diane, et al.
Publicado: (2022)

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
por: Berger, Alice H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uetg4geau25ovcf3rmpgof25ij